ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2019

May 30, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2019-05-24

Reporting Person: Anzalone Christopher Richard (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-05-24	Common Stock	M	40072	$2.01	Acquired	2132527	Direct
2019-05-24	Common Stock	M	9376	$2.62	Acquired	2141903	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-05-24	Stock Option (right to buy)	$2.01	M	40072	Disposed	2023-05-06	Common Stock (40072)	Direct
2019-05-24	Stock Option (right to buy)	$2.62	M	9376	Disposed	2022-09-28	Common Stock (9376)	Direct

Footnotes

F1: Includes a total of 933,333 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole.

F2: Represents first vesting date. Option vested over four years from date of grant.